反应详情

A mixture of tert-butyl(S)-6-hydroxy-4-(6-(6-(1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)pyridin-2-yl)-1,4-diazepane-1-carboxylate (70 mg, 0.13 mmol) in HCl/MeOH (4.0 M, 10 mL) was stirred at room temperature for 3 hours, which was monitored by LCMS. After completion of the reaction, the reaction mixture was concentrated under reduced pressure. The crude material was purified by reverse phase prep-HPLC to afford (R)-1-(6-(6-(1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridine-1-yl)pyridin-2-yl)-1,4-diazepan-6-ol 188 as a white solid (30 mg, 52.6%). 1H NMR (500 MHz, DMSO-d6) δ (ppm) 9.16 (s, 1H), 8.74 (s, 1H), 8.55 (s, 1H), 8.49 (s, 1H), 8.21 (s, 1H), 7.69 (t, J=16 Hz, 1H), 7.17 (d, J=7.5 Hz, 1H), 6.66 (d, J=8 Hz, 1H), 5.18-5.24 (m, 2H), 4.93 (d, J=5.5 Hz, 1H), 3.96 (t, J=8.5 Hz, 1H), 3.88 (m, 2H), 3.56-3.64 (m, 2H), 2.98 (t, J=10.5 Hz, 2H), 2.80-2.84 (m, 1H), 2.64-2.72 (m, 1H); MS (ESI) m/z: 459 [M+H]+.

1. customAfter completion of the reaction
2. concentrationthe reaction mixture was concentrated under reduced pressure
3. customThe crude material was purified by reverse phase prep-HPLC